iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations

Read also

uniQure Staggers as FDA Questions Data for Huntington’s Gene Therapy Candidate

Agency torpedoes company's plans to submit BLA for gene therapy AMT-130 in Q1 2026.

Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn

Kimberly-Clark has agreed to acquire Johnson & Johnson (J&J) consumer health spinout Kenvue for $48.7bn.

Femasys gets FDA OK for final FemBloc trial, secures $12M financing, stock surges

Femasys (FEMY) on Monday said that the FDA  approved continuation of the final phase of its FemBloc pivotal trial, sending shares 25% higher in premarket trading.

Praxis announces

Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback